CTLA-4 ligation blocks CD28-dependent T cell activation
- PMID: 8676075
- PMCID: PMC2192609
- DOI: 10.1084/jem.183.6.2541
CTLA-4 ligation blocks CD28-dependent T cell activation
Erratum in
- J Exp Med 1996 Jul 1;184(1):301
Abstract
CTLA-4 is a CD28 homologue believed to be a negative regulator of T cell function. However, the mechanism of this downregulatory activity is not well understood. The present study was designed to examine the effect of CTLA-4 ligation on cytokine production, cell survival, and cell cycle progression. The results demonstrate that the primary effect of CTLA-4 ligation is not the induction of apoptosis. Instead, CTLA-4 signaling blocks IL-2 production, IL-2 receptor expression, and cell cycle progression of activated T cells. Moreover, the effect of CTLA-4 signaling was manifested after initial T cell activation. Inhibition of IL-2 receptor expression and cell cycle progression was more pronounced at late (72 h) time points after initial activation. The effects of anti-CTLA-4 mAbs were most apparent in the presence of optimal CD28-mediated costimulation consistent with the finding that CTLA-4 upregulation was CD28-dependent. Finally, the addition of exogenous IL-2 to the cultures restored IL-2 receptor expression and T cell proliferation. These results suggest that CTLA-4 signaling does not regulate cell survival or responsiveness to IL-2, but does inhibit CD28-dependent IL-2 production.
Similar articles
-
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.J Exp Med. 1996 Jun 1;183(6):2533-40. doi: 10.1084/jem.183.6.2533. J Exp Med. 1996. PMID: 8676074 Free PMC article.
-
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.J Exp Med. 1992 Dec 1;176(6):1595-604. doi: 10.1084/jem.176.6.1595. J Exp Med. 1992. PMID: 1334116 Free PMC article.
-
CTLA-4 can function as a negative regulator of T cell activation.Immunity. 1994 Aug;1(5):405-13. doi: 10.1016/1074-7613(94)90071-x. Immunity. 1994. PMID: 7882171
-
Expression and functional significance of CTLA-4, a negative regulator of T cell activation.Arch Immunol Ther Exp (Warsz). 2001;49(1):39-46. Arch Immunol Ther Exp (Warsz). 2001. PMID: 11266089 Review.
-
CD28: a signalling perspective.Biochem J. 1996 Sep 1;318 ( Pt 2)(Pt 2):361-77. doi: 10.1042/bj3180361. Biochem J. 1996. PMID: 8809021 Free PMC article. Review.
Cited by
-
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. J Leukoc Biol. 2013. PMID: 23625198 Free PMC article. Review.
-
Inborn Errors of Immunity and Cytokine Storm Syndromes.Adv Exp Med Biol. 2024;1448:185-207. doi: 10.1007/978-3-031-59815-9_14. Adv Exp Med Biol. 2024. PMID: 39117816 Review.
-
Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer.Front Cell Dev Biol. 2016 Oct 17;4:108. doi: 10.3389/fcell.2016.00108. eCollection 2016. Front Cell Dev Biol. 2016. PMID: 27800476 Free PMC article. Review.
-
The role of coinhibitory signaling pathways in transplantation and tolerance.Front Immunol. 2012 Mar 19;3:47. doi: 10.3389/fimmu.2012.00047. eCollection 2012. Front Immunol. 2012. PMID: 22566929 Free PMC article.
-
Serum sCTLA-4 levels and clinical manifestations in ankylosing spondylitis patients.Eur J Rheumatol. 2018 Jul;5(2):115-117. doi: 10.5152/eurjrheum.2018.17114. Epub 2018 Jan 22. Eur J Rheumatol. 2018. PMID: 30185360 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources